A compound of Formula (I) wherein R x represents C 1-4 alkyl, or C 3-6 cycloalkyl; R y represents C 1-4 alkyl; and R z represents hydrogen; R 1 is selected from the group consisting of hydrogen, -OR 5 , C 1-4 alkyl, C 2-4 alkenyl, halo, -CN, C 3-6 cycloalkyl, Het a , -C(=O)-OH, -C(=O)-O-C 1-4 alkyl, -NR 6a R 7a and -C(=O)-NR 6b R 7b ; R 2a and R 2b are each independently selected from the group consisting of hydrogen, -NR 6c R 7c , C 3-6 cycloalkyl, C 1-4 alkyl, and C 1-4 alkyl substituted with 1, 2 or 3 halo atoms; X 1 represents N or CR a ; X 2 represents N or CR b ; such that only one of X 1 and X 2 are N in any instance; R 3 represents hydrogen, C 1-4 alkyl or -O-C 1-4 alkyl; R 4 represents halo, cyano or trifluoromethyl; R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, Het b , and C 1-4 alkyl substituted with one or two substituents each independently selected from the group consisting of -C(=O)-NR 8 R 9 , -C(=O)-OH, -C(=O)-O-C 1-4 alkyl, C 3-6 cycloalkyl and phenyl; R 6a , R 6b , R 6c , R 7a , R 7b , R 7c , R 8 and R 9 each independently are selected from the group consisting of hydrogen and C 1-4 alkyl; Het a represents a monocyclic 4- to 7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulfur; Het b represents a monocyclic 4- to 7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulfur; R a represents -O-C 1-4 alkyl, each optionally substituted with one, two or three halo substituents; or R a represents 2H-1,2,3-triazol-2-yl or C 3-6 cycloalkyl; each optionally substituted on one carbon atom with a substituent each independently selected from the group consisting of C 1-4 alkyl, and C 1-4 alkyl substituted with one -OH; R b represents hydrogen; or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof. R x represents C 1-4 alkyl, or C 3-6 cycloalkyl; R y represents C 1-4 alkyl; and R z represents hydrogen; R 1 is selected from the group consisting of hydrogen, -OR 5 , C 1-4 alkyl, C 2-4 alkenyl, halo, -CN, C 3-6 cycloalkyl, Het a , -C(=O)-OH, -C(=O)-O-C 1-4 alkyl, -NR 6a R 7a and -C(=O)-NR 6b R 7b ; R 2a and R 2b are each independently selected from the group consisting of hydrogen, -NR 6c R 7c , C 3-6 cycloalkyl, C 1-4 alkyl, and C 1-4 alkyl substituted with 1, 2 or 3 halo atoms; X 1 represents N or CR a ; X 2 represents N or CR b ; such that only one of X 1 and X 2 are N in any instance; R 3 represents hydrogen, C 1-4 alkyl or -O-C 1-4 alkyl; R 4 represents halo, cyano or trifluoromethyl; R 5 is selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, Het b , and C 1-4 alkyl substituted with one or two substituents each independently selected from the group consisting of -C(=O)-NR 8 R 9 , -C(=O)-OH, -C(=O)-O-C 1-4 alkyl, C 3-6 cycloalkyl and phenyl; R 6a , R 6b , R 6c , R 7a , R 7b , R 7c , R 8 and R 9 each independently are selected from the group consisting of hydrogen and C 1-4 alkyl; Het a represents a monocyclic 4- to 7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulfur; Het b represents a monocyclic 4- to 7-membered non-aromatic heterocyclyl containing one or two heteroatoms selected from nitrogen, oxygen and sulfur; R a represents -O-C 1-4 alkyl, each optionally substituted with one, two or three halo substituents; or R a represents 2H-1,2,3-triazol-2-yl or C 3-6 cycloalkyl; each optionally substituted on one carbon atom with a substituent each independently selected from the group consisting of C 1-4 alkyl, and C 1-4 alkyl substituted with one -OH; R b represents hydrogen; or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt form thereof. <EOS>